Moti Ramgopal

5.1k citations

83 papers · 1.5k indexed · h-index 21

Impact in

Virology top 0.5%
- HIV Research and Treatment
Infectious Diseases top 1%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Virology 37
- HIV Research and Treatment 37
Infectious Diseases 69
- HIV/AIDS drug development and treatment 55
- HIV/AIDS Research and Interventions 31

Co-authors: Rémi Fromentin (4 shared papers)Nicolas Chomont (4 shared papers)Claire Vandergeeten (3 shared papers)Sandrina DaFonseca (2 shared papers)Mariam B. Lawani (2 shared papers)Jean‐Pierre Routy (3 shared papers)Gordon Crofoot (9 shared papers)Rafick‐Pierre Sékaly (1 shared paper)
Journals: Open Forum Infectious Diseases (22 papers)Clinical Infectious Diseases (7 papers)The Lancet HIV (6 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (4 papers)AIDS (4 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Moti Ramgopal

73 papers receiving 1.5k citations

Peers

Countries citing papers authored by Moti Ramgopal

Since Specialization

Citations

This map shows the geographic impact of Moti Ramgopal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moti Ramgopal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moti Ramgopal more than expected).

Fields of papers citing papers by Moti Ramgopal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moti Ramgopal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moti Ramgopal. The network helps show where Moti Ramgopal may publish in the future.

Co-authors

The 25 scholars most cited alongside Moti Ramgopal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Moti Ramgopal Line = papers co-authored together Moti Ramgopal links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 83 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Interleukin-7 promotes HIV persistence during antiretroviral therapy Blood ·Claire Vandergeeten, Rémi Fromentin, Sandrina DaFonseca, Mariam B. Lawani, Irini Sereti, Michael M. Lederman, Moti Ramgopal, Jean‐Pierre Routy, Rafick‐Pierre Sékaly, Nicolas Chomont	2013	183
2	Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anton Pozniak, José Ramón Arribas, Joseph Gathe, Samir K. Gupta, Frank A. Post, Mark Bloch, Anchalee Avihingsanon, Gordon Crofoot, Paul Benson, Kenneth Lichtenstein, Moti Ramgopal, Ploenchan Chetchotisakd, Joseph M. Custodio, Michael E. Abram, Xuelian Wei, Andrew Cheng, Scott McCallister, Devi SenGupta, Marshall W. Fordyce	2015	158
3	Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies Journal of Virology ·Claire Vandergeeten, Rémi Fromentin, Esther Merlini, Mariam B. Lawani, Sandrina DaFonseca, Wendy Bakeman, Amanda McNulty, Moti Ramgopal, Nelson L. Michael, Jérôme H. Kim, Jintanat Ananworanich, Nicolas Chomont	2014	156
4	Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial The Lancet HIV ·David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie Thompson, Cynthia Brinson, Debbie Hagins, Moti Ramgopal, Andrea Antinori, Xuelian Wei, Rima Acosta, Sean E Collins, Diana M. Brainard, Hal Martin	2019	116
5	Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART Nature Communications ·Pierre Gantner, Amélie Pagliuzza, Marion Pardons, Moti Ramgopal, Jean‐Pierre Routy, Rémi Fromentin, Nicolas Chomont	2020	69
6	Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment AIDS Research and Human Retroviruses ·Edwin DeJesus, Bernard Haas, Sorana Segal‐Maurer, Moti Ramgopal, Anthony Mills, Nicolas Margot, Ya-Pei Liu, Tariro Makadzange, Scott McCallister	2018	67
7	Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial The Lancet HIV ·Samir K. Gupta, Mezgebe Berhe, Gordon Crofoot, Paul Benson, Moti Ramgopal, James J. Sims, Cheryl McDonald, Peter Ruane, William E Sanchez, Anita Scribner, Shanyu Liu, Laurie A. VanderVeen, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Ellen Koenig	2022	65
8	Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study Antiviral Therapy ·Bisher Akil, Gary Blick, Debbie Hagins, Moti Ramgopal, Gary Richmond, Rafik Samuel, Naomi Givens, Cindy Vavro, Ivy Song, Brian Wynne, Mounir Ait‐Khaled, (unknown)	2014	61
9	Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains PLoS ONE ·Ivette A. Nuñez, Michael A. Carlock, James D. Allen, Simon O. Owino, Krissy Moehling Geffel, Patricia Nowalk, Michael Susick, Kensington Diagle, Kristen Sweeney, Sophia T. Mundle, Thorsten U. Vogel, Simon Delagrave, Moti Ramgopal, Richard K. Zimmerman, Harry Kleanthous, Ted M. Ross	2017	58
10	12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens Clinical Infectious Diseases ·Anne F. Luetkemeyer, Cheryl McDonald, Moti Ramgopal, Stephanie Noviello, Rafia Bhore, Peter Ackerman	2016	45
11	Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study The Lancet HIV ·Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Claudia Martorell, Joseph de Wet, Hans‐Jürgen Stellbrink, Jean‐Michel Molina, Frank A. Post, Ignacio Valero, Danielle Porter, Ya-Pei Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao	2017	37
12	Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV AIDS ·Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson K Wurapa, Moti Ramgopal, Peter A. Leone, Jessica Matthews, Marybeth Dalessandro, Mark Underwood, Konstantinos Angelis, Brian Wynne, Deanna Merrill, Christopher Nguyen, Jean van Wyk, Andrew Zolopa	2021	34
13	Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses Human Vaccines & Immunotherapeutics ·Michael A. Carlock, John G. Ingram, Emily F. Clutter, Noah C. Cecil, Moti Ramgopal, Richard K. Zimmerman, W. L. Warren, Harry Kleanthous, Ted M. Ross	2019	28
14	Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study JAIDS Journal of Acquired Immune Deficiency Syndromes ·Debbie Hagins, Princy Kumar, Michael S. Saag, Anson K Wurapa, Indira Brar, Daniel Berger, Olayemi Osiyemi, Corrilynn O. Hileman, Moti Ramgopal, Cheryl McDonald, Christiana Blair, Kristen Andreatta, Sean E Collins, Diana M. Brainard, Hal Martin, (unknown)	2021	28
15	Origin of the dengue virus outbreak in Martin County, Florida, USA 2013 SHILAP Revista de lepidopterología ·Frank D. Teets, Moti Ramgopal, Kristen Sweeney, Amanda S. Graham, Scott F. Michael, Sharon Isern	2014	26
16	Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study SHILAP Revista de lepidopterología ·Miranda Murray, Federico Pulido, Anthony Mills, Moti Ramgopal, Roger LeBlanc, Hans Jaeger, (unknown), David Dorey, Sandy Griffith, Joseph Mrus, William Spreen, David M. Margolis	2019	26
17	Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study Clinical Infectious Diseases ·Gregory Huhn, Gordon Crofoot, Moti Ramgopal, Joseph Gathe, Robert Bolan, Donghan Luo, Richard Bruce Simonson, Richard E. Nettles, Carmela Benson, Keith Dunn	2019	25
18	Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study The Lancet HIV ·Joseph J. Eron, Susan J. Little, Gordon Crofoot, Paul Cook, Peter Ruane, Dushyantha Jayaweera, Laurie A. VanderVeen, Edwin DeJesus, Yanan Zheng, Anthony Mills, Hailin Huang, Sarah Waldman, Moti Ramgopal, Linda Gorgos, Sean E Collins, Jared M. Baeten, Marina Caskey	2024	24
19	Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial Infection ·Matthew G. Johnson, Julie Strizki, Michelle Brown, Hong Wan, Hala Shamsuddin, Moti Ramgopal, Diana F. Florescu, Pierre Delobel, И. М. Хаертынова, José F. Flores, Leon F. Fouche, Shan‐Chwen Chang, Angela Williams‐Diaz, Jiejun Du, Jay A. Grobler, Amanda Paschke, Carisa De Anda	2023	23
20	Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP) PLoS ONE ·Michelle Cespedes, Moupali Das, J. Carlo Hojilla, Jill Blumenthal, Karam Mounzer, Moti Ramgopal, Theo Hodge, Thiago S. Torres, Charles M. Peterson, Senzokuhle Shibase, Ayana Elliott, A. C. Demidont, Larkin Callaghan, Christopher Chauncey Watson, Christoph C Carter, Alex Kintu, Jared M. Baeten, Onyema Ogbuagu	2022	23

About Moti Ramgopal

Moti Ramgopal is a scholar working on Virology, Infectious Diseases, Emergency Medicine, Microbiology and Hepatology, having authored 83 papers that have together received 1.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (55 papers), HIV Research and Treatment (37 papers), HIV/AIDS Research and Interventions (31 papers), HIV-related health complications and treatments (23 papers), Hepatitis C virus research (10 papers), Pharmacological Effects and Toxicity Studies (8 papers), Hepatitis B Virus Studies (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Virology (901 citations), Infectious Diseases (1.1k citations), Emergency Medicine (322 citations), Hepatology (125 citations) and Epidemiology (418 citations). Moti Ramgopal has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Rémi Fromentin, Nicolas Chomont, Claire Vandergeeten, Sandrina DaFonseca, Mariam B. Lawani, Jean‐Pierre Routy, Gordon Crofoot, Rafick‐Pierre Sékaly, Irini Sereti and Xuelian Wei. Their work appears in journals such as Open Forum Infectious Diseases, Clinical Infectious Diseases, The Lancet HIV, JAIDS Journal of Acquired Immune Deficiency Syndromes and AIDS.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact